150 million to buy Guangdong Qing FA

For the excess to raise funds up to more than 3 billion yuan in the Cologne pharmaceutical industry (002422. SZ), how to make good use of these funds is obviously the most important.　　After the acquisition of Zhejiang counterparts last month, the Cologne pharmaceutical industry announced today, will spend 148 million yuan to buy Guangdong Qing FA Pharmaceutical Co., Ltd. (hereinafter referred to as "Guangdong Qing fa"). Cologne pharmaceutical industry announced today that the company in recent years with Guangdong Sanvi Bio-Pharmaceutical Group Co., Ltd. Guangdong and the natural person Zhang Yu signed the "Equity transfer Agreement", the company agreed to buy 24.3 million yuan of the two total holdings of Guangdong Qing FA 100% Equity,　　And to bear the Guangdong Qing hair as of the end of this year, including litigation or arbitration of no more than 123.7 million yuan of all debts. After the completion of the acquisition, the Cologne pharmaceutical industry will hold a 100% stake in the Guangdong Qing fa. The company will use the super raise funds 24.3 million yuan to pay for the transfer of equity, the use of over 123.7 million yuan to raise funds through the wholly-owned subsidiary of Guangdong Qing FA financial assistance to repay the related debt.　　According to this calculation, the company will spend 148 million yuan for this acquisition. In fact, the acquisition is not the first time for the Cologne industry.　　Data show that the Cologne pharmaceutical industry this year, the IPO over 3.281 billion yuan raise funds. November 10 this year, the company and Zhejiang National Mirror Pharmaceutical Co., Ltd., the main shareholder Cai 4 people signed the "Equity transfer Agreement", the Cologne pharmaceutical companies to use over 247 million yuan acquisition of Cai and other 4 shareholders held by the Zhejiang Mirror 85% equity.